For example, rituximab and trastuzumab are widely used for therapy of patients with B-cell non-Hodgkin ́s lymphoma and human epidermal growth factor receptor 2 (HER2)-positive breast cancer, respectively [2,3]. Here, ERBB2 is linked to breast carcinoma.